Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

<br xmlns:etd="http://www.ouls.ox.ac.uk/ora/modsextensions"><strong>Background: </strong>There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and β-amyloid 42 (Aβ42) peptid...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Tapiola, T, Alafuzoff, I, Herukka, S, Parkkinen, L, Hartikainen, P, Soininen, H, Pirttilä, T
Μορφή:	Journal article
Έκδοση:	American Medical Association 2009

Παρόμοια τεκμήρια

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
ανά: Mandić Gorana, κ.ά.
Έκδοση: (2008-01-01)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
ανά: Rosengren Lars, κ.ά.
Έκδοση: (2009-12-01)

Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau.
ανά: Aysha S Mohamed Lafirdeen, κ.ά.
Έκδοση: (2019-01-01)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
ανά: Katherine W. Turk, κ.ά.
Έκδοση: (2022-02-01)

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
ανά: Sun Ah Park, κ.ά.
Έκδοση: (2020-04-01)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
ανά: Ross W. Paterson, κ.ά.
Έκδοση: (2015-09-01)

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.
ανά: Mony J de Leon, κ.ά.
Έκδοση: (2018-01-01)

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease
ανά: Parkkinen, L, κ.ά.
Έκδοση: (2003)

PET tau and amyloid-β burden in mild Alzheimer's disease: divergent relationship with age, cognition and cerebrospinal fluid biomarkers
ανά: Koychev, I, κ.ά.
Έκδοση: (2017)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
ανά: Longfei Jia, κ.ά.
Έκδοση: (2021-11-01)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
ανά: Caterina Motta, κ.ά.
Έκδοση: (2023-08-01)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1‐42 in Alzheimer's Disease Neuroimaging Initiative participants
ανά: Wei Li, κ.ά.
Έκδοση: (2018-01-01)

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.
ανά: Mikko Hölttä, κ.ά.
Έκδοση: (2013-01-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
ανά: Eline A.J. Willemse, κ.ά.
Έκδοση: (2017-01-01)

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
ανά: Parkkinen, L, κ.ά.
Έκδοση: (2008)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
ανά: Elmar Kaiser, κ.ά.
Έκδοση: (2011-11-01)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
ανά: Yuk Yee Leung, κ.ά.
Έκδοση: (2015-09-01)

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
ανά: Jinny Claire Lee, κ.ά.
Έκδοση: (2019-05-01)

Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.
ανά: Jin-A Mo, κ.ά.
Έκδοση: (2015-01-01)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
ανά: Taylor J. Maxwell, κ.ά.
Έκδοση: (2018-08-01)

Aβ42 as a Biomarker of Alzheimer’s Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
ανά: Silvia Boschi, κ.ά.
Έκδοση: (2022-12-01)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
ανά: Giacomo Stroffolini, κ.ά.
Έκδοση: (2021-11-01)

Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects
ανά: Aho, L, κ.ά.
Έκδοση: (2008)

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject
ανά: Parkkinen, L, κ.ά.
Έκδοση: (2005)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
ανά: Niels Kruse, κ.ά.
Έκδοση: (2016-01-01)

Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains
ανά: Xin-Wen Zhou, κ.ά.
Έκδοση: (2006-06-01)

Cerebrospinal fluid β2-microglobulin promotes the tau pathology through microglia–astrocyte communication in Alzheimer's disease
ανά: Zehu Sheng, κ.ά.
Έκδοση: (2025-01-01)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
ανά: Umesh Gangishetti, κ.ά.
Έκδοση: (2018-09-01)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
ανά: Parkkinen, L, κ.ά.
Έκδοση: (2004)

Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer’s disease and other neurodegenerative diseases
ανά: Masanori Kurihara, κ.ά.
Έκδοση: (2024-03-01)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
ανά: Emmanuelle Duron, κ.ά.
Έκδοση: (2018-10-01)

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
ανά: Sang Su Kwak, κ.ά.
Έκδοση: (2020-03-01)

Mobility and associations with levels of cerebrospinal fluid amyloid β and tau in a memory clinic cohort
ανά: Gro Gujord Tangen, κ.ά.
Έκδοση: (2023-02-01)

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease
ανά: Marina Arcaro, κ.ά.
Έκδοση: (2022-10-01)

A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease
ανά: Keerthanaa Balasubramanian Shanthi, κ.ά.
Έκδοση: (2015-08-01)

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
ανά: Patel Sunil, κ.ά.
Έκδοση: (2012-03-01)

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms
ανά: Parkkinen, L, κ.ά.
Έκδοση: (2007)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
ανά: Sebastian Palmqvist, κ.ά.
Έκδοση: (2019-11-01)

Cerebrospinal fluid of Alzheimer patients promotes β-amyloid fibril formation in vitro
ανά: Kenjiro Ono, κ.ά.
Έκδοση: (2005-11-01)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
ανά: Mychael V. Lourenco, κ.ά.
Έκδοση: (2020-01-01)